NASH Archives - WuXi Biology

Enhancing Treatment of MASH with Combination Therapies

Metabolic dysfunction-associated steatohepatitis (MASH) remains a significant global health challenge, driven by a complex interplay of lipid dysregulation, inflammation, and...

Innovative Animal Models for MASH Drug Development

Integrating drug targets, molecular types, and clinical translation Introduction: Metabolic dysfunction-associated steatohepatitis (MASH), a growing global health concern, has garnered...

Emerging Role of GLP-1 Receptor Agonists for the Treatment of MASH

Abstract: Emerging as a major global health concern, metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to obesity, type 2 diabetes,...

Hepatobiliary Disease Platform

The hepatobiliary system (comprised of the liver, gallbladder, and bile ducts) plays an important role in digestion and in the...

Fibrosis Models in Mice and Rats

Selecting preclinical in vivo models that are reflective of clinical outcome is a key challenge in the development of new...

Translational Pharmacology of CNS and Metabolic Disorders for Testing New Modality Therapies

Animal studies may provide a close approximation to humans when addressing the key challenge of clinical translatability. In the preclinical...

Case Study: Clinically Relevant NASH Animal Model

In this case study, we demonstrate clinical relevance of the HFD+CCL4 (high-fat diet and carbon tetrachloride) NASH animal model. Improvement...

Quantitative Histopathology of Fibrosis in an Animal Model of NASH

The hepatic fibrosis has been the most challenging aspect in the animal models for nonalcoholic steatohepatitis (NASH). Although it could...

Knowledge Library